Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
96 hedge funds and large institutions have $374M invested in Y-mAbs Therapeutics in 2024 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 25 increasing their positions, 44 reducing their positions, and 18 closing their positions.
168% more capital invested
Capital invested by funds: $140M → $374M (+$234M)
11% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 18
5.61% more ownership
Funds ownership: 46.95% → 52.56% (+5.6%)
2% more funds holding
Funds holding: 94 → 96 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less call options, than puts
Call options by funds: $748K | Put options by funds: $808K
43% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
+$30.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.6M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$10.1M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$5.58M |
| 5 |
Millennium Management
New York
|
+$3.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CP
Caligan Partners
New York
|
-$6.22M |
| 2 |
BFM
Boothbay Fund Management
New York
|
-$4.68M |
| 3 |
Morgan Stanley
New York
|
-$4.07M |
| 4 |
D.E. Shaw & Co
New York
|
-$3.45M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$3.09M |
YMAB Hedge Fund Activity: Q1 2024 in Review
96 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2024, worth a combined $374M — up 168% from $140M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new YMAB positions and 18 closed out — a net gain of 2 holders — while 25 added to existing stakes and 44 trimmed.
The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $30.1M. The largest seller was Caligan Partners, cutting an estimated $6.22M.
- 96 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2024, up from 94 in Q4 2023.
- Funds reported $374M of Y-mAbs Therapeutics stock for Q1 2024, up 168% quarter-over-quarter.
- 20 funds opened new Y-mAbs Therapeutics positions in Q1 2024 and 18 closed out, a net change of +2 holders.
- The largest Y-mAbs Therapeutics buyer in Q1 2024 was Paradigm Biocapital Advisors, an estimated $30.1M added.
- The largest Y-mAbs Therapeutics seller in Q1 2024 was Caligan Partners, an estimated $6.22M sold.
Based on aggregated 13F filings for Q1 2024.